In-center Nocturnal Hemodialysis Reduced the Circulating FGF23, Left Ventricular Hypertrophy, and All-Cause Mortality: A Retrospective Cohort Study

In-center Nocturnal Hemodialysis Reduced the Circulating FGF23, Left Ventricular Hypertrophy, and All-Cause Mortality: A Retrospective Cohort Study

Fibroblast growth factor 23(FGF23) is the most important biomarker and pathogenic factor in Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD). In the moderate and severe stages of chronic renal failure, abnormally elevated circulating FGF23 can lead to some complications, including myocardi...

Full description

Bibliographic Details
Main Authors: Meizi Kang, Jing Chen, Lingling Liu, Cheng Xue, Xiaojing Tang, Jiayi Lv, Lili Fu, Changlin Mei, Zhiguo Mao, Yawei Liu, Bing Dai
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Medicine
Subjects:
in-center nocturnal hemodialysis
fibroblast growth factor 23
Chronic Kidney DiseaseMineral and Bone Disorder (CKD-MBD)
calcium-phosphate product
left ventricular hypertrophy
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.912764/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.912764/full

Similar Items